Google AI for Health Program Selects Five African Startups

By HEOR Staff Writer

October 26, 2023

AI for Health program

A New Era for African Health Startups

The 2023 cohort of the Google for Startups Growth Academy: AI for Health program has been announced. The aforementioned selection comprises a total of 30 startup companies. All originating from the regions of Europe, the Middle East, and Africa. Out of the selection, five African firms have been designated, namely mDoc and PharmaRun from Nigeria.

The selection of these firms is based on their utilization of artificial intelligence (AI) in a pioneering manner to address health-related obstacles. They have the potential to enhance healthcare by implementing artificial intelligence (AI)-based solutions. This encompasses a wide range of areas, spanning from the early diagnosis of diseases to the promotion of universal access to information.

 

The Conceptual Framework Underlying the Program

Yuval Passov, the Head of Google for entrepreneurs, articulated his perspective on the potential of African health entrepreneurs utilizing artificial intelligence (AI). The author found Africa’s pioneering attitude in the field of AI for Health to be highly motivating. The chosen startups serve as evidence of the continent’s capacity to create worldwide health solutions. Google’s objective is to align itself with these entities, providing assistance and collaboration as they endeavor to expand and distribute their innovative solutions.

The Google for businesses Growth Academy: AI for Health program aligns with Google’s goal to help businesses grow faster. This program aims to support selected African and international companies. It strives to encourage innovation and healthcare advancements. Ultimately, it seeks to create a lasting positive impact on global welfare.

Reference url

Recent Posts

FDA Approval Lumvoa Therapeutics
FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease

By João L. Carapinha

June 29, 2026

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.
HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...